艾切托 ACET 深滬

等待開盤 12-23 09:30:00 美东时间

0.4902

-0.003

-0.71%

華盛通

立即下載

最高0.5184
今開0.49
成交量 183.32万股
最低 0.4865
昨收 0.4937
總市值 7500.06万
52周最高 1.11
市盈率 ^靜 --
換手率 1.20%
52周最低 0.4471
委比 22.70%
總股本 1.53亿
歷史最高 225.40
量比 0.66
振幅 6.46%
歷史最低 0.4471
每手 1
風險率 0.14%

個股概要

財務分析

公司資料

分紅派息

分時圖
日k
周k
月k

相關新聞

美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级

今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元

11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级

今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元

11-10 10:22
HC Wainwright & Co. Maintains Buy on Adicet Bio, Raises Price Target to $9

HC Wainwright & Co. analyst Robert Burns maintains Adicet Bio (NASDAQ:ACET) with a Buy and raises the price target from $4 to $9.

11-07 20:38
MaxCyte Reports Preliminary Q3 Revenue of $6.8M And Reiterates Its 2025 Revenue Guidance

MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its preliminary results for the third quarter ended September 30, 2025 and reiterated its 2025 revenue g

11-05 21:24
2025 Q3生物制药裁员汇总

（来源：药研网）金秋十月，凉风拂过，却未能带来行业期盼已久的复苏。国外媒体Fierce Biotech 最新数据显示，刚过去的第三季度，共发生 62 起裁员...

10-09 14:47
Adicet Bio Receives Nasdaq Extension for Compliance

The latest update is out from Adicet Bio ( ($ACET) ). On October 7, 2025, Adice...

10-08 04:36
Adicet Bio Announces Major Stock Offering Agreement

Adicet Bio ( ($ACET) ) just unveiled an update. On October 7, 2025, Adicet Bio,...

10-07 19:28
Adicet Bio launches $80M securities offering

Adicet Bio (NASDAQ:ACET) announced an underwritten direct offering of 70 million shares of common stock and, for certain investors, pre-funded warrants to buy 10 million shares. The common stock is pr...

10-07 19:13
Adicet Bio Shares Initial Safety And Efficacy Data From The First Seven Patients Dosed With ADI-001 In The Ongoing Phase 1 Study In Patients With Autoimmune Diseases

Clinical data to date supports a potentially transformational approach to treating autoimmune diseases with an off-the-shelf, one-time therapy.As of the August 31, 2025 data cut-off date, all seven evaluable LN and SLE

10-07 18:51
SPACETALK Limited Announces Director’s Shareholding Adjustment

SPACETALK Limited ( ($AU:SPA) ) just unveiled an announcement. SPACETALK Limite...

10-06 09:58

派息除權日	每股總股息	派息日期
2018-09-21	0.010	2018-10-09
2018-06-07	0.010	2018-06-22
2018-03-08	0.06	2018-03-23
2017-12-15	0.06	2017-12-28
2017-09-07	0.06	2017-09-21
2017-06-07	0.06	2017-06-23
2017-03-08	0.06	2017-03-24
2016-12-08	0.06	2016-12-22
2016-09-07	0.06	2016-09-20
2016-06-07	0.06	2016-06-24
2016-03-09	0.06	2016-03-25
2015-12-15	0.06	2015-12-28
2015-09-17	0.06	2015-10-02
2015-06-09	0.06	2015-06-25
2015-03-10	0.06	2015-03-26
2014-12-11	0.06	2014-12-29
2014-09-11	0.06	2014-09-29
2014-06-10	0.06	2014-06-27
2014-03-11	0.06	2014-03-28
2013-12-12	0.06	2013-12-27
2013-09-12	0.06	2013-09-27
2013-06-12	0.05	2013-06-25
2013-03-13	0.05	2013-03-26
2012-12-13	0.05	2012-12-28
2012-09-13	0.05	2012-09-28
2012-06-07	0.10	2012-06-22
2011-12-23	0.10	2012-01-18
2011-06-09	0.10	2011-06-24
2010-12-22	0.10	2011-01-21
2010-06-10	0.10	2010-06-25
2009-12-22	0.10	2010-01-15
2009-06-11	0.10	2009-06-26
2008-12-17	0.10	2009-01-13
2008-06-12	0.10	2008-06-27
2008-02-20	0.05	2008-03-07
2007-12-19	0.10	2008-01-11
2007-06-14	0.10	2007-06-28
2006-12-20	0.08	2007-01-12
2006-06-15	0.08	2006-06-29
2005-12-21	0.08	2006-01-11
2005-06-16	0.08	2005-06-30
2004-12-21	0.11	2005-01-10
2004-06-10	0.09	2004-06-25
2003-12-15	0.13	2004-01-02
2003-06-12	0.12	2003-06-27
2002-12-16	0.17	2003-01-02
2002-06-13	0.16	2002-06-28
2001-12-17	0.16	2002-01-02
2001-06-14	0.16	2001-06-29
2000-12-15	0.15	2001-01-02
2000-06-15	0.15	2000-06-29
1999-12-16	0.15	2000-01-03
1999-06-11	0.13	1999-06-29
1998-12-17	0.13	1999-01-04
1998-06-12	0.13	1998-06-30
1998-06-10	0.13	1998-06-30
1997-12-15	0.18	1998-01-05
1997-06-12	0.18	1997-06-30
1996-12-12	0.18	1997-01-02
1996-06-13	0.18	1996-06-28
1995-12-14	0.20	1996-01-02
1995-06-15	0.18	1995-06-29
1994-12-12	0.18	1995-01-03
1994-06-14	0.16	1994-06-29
1993-12-13	0.16	1994-01-03
1993-06-15	0.14	1993-06-29
1992-12-14	0.17	1993-01-01
1992-06-16	0.14	1992-06-30
1991-12-09	0.14	1992-01-02
1991-06-04	0.14	1991-06-28
1990-12-10	0.14	1991-01-01
1990-06-05	0.07	1990-07-01
1989-11-27	0.50	1989-12-15
1989-06-06	0.07	1989-07-01
1988-12-12	0.07	1989-01-01
1988-10-24	0.50	1988-11-10
1988-06-07	0.07	1988-07-01
1988-03-30	1.25	1988-04-14
1987-12-15	0.07	1988-01-04
1987-06-08	0.07	1987-07-01
1986-10-07	0.07	1986-10-29
1986-03-24	0.07	1986-04-25
1985-10-22	0.07	1985-11-01
1984-10-02	0.04	1984-10-26
1984-03-26	0.04	1984-04-27
1983-10-04	0.04	1983-10-28
1983-03-28	0.04	1983-04-29
1982-10-05	0.04	1982-10-29
1982-03-30	0.03	1982-04-30
1981-10-06	0.03	1981-10-30
1981-03-31	0.03	1981-05-01
1980-10-07	0.03	1980-10-31
1980-03-30	0.10	1980-05-02
1979-09-30	0.03	1979-11-01
1978-12-10	0.05	1979-01-04
1978-01-08	0.05	1978-01-30
1976-12-27	0.05	1977-01-27
1975-12-25	0.05	1976-01-22

公司名稱	艾切托
行業分類	制药
業務描述	Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. It also focuses on developing a pipeline of 'off-the-shelf' gamma delta T cells. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.

艾切托 ACET 深 滬

0.4902

個股概要

財務分析

公司資料

相關新聞

分紅派息

相關新聞

公司簡介

艾切托 ACET 深滬